These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 11792569)

  • 1. Macrophage colony-stimulating factor and receptor activator NF-kappaB ligand fail to rescue osteoclast-poor human malignant infantile osteopetrosis in vitro.
    Flanagan AM; Massey HM; Wilson C; Vellodi A; Horton MA; Steward CG
    Bone; 2002 Jan; 30(1):85-90. PubMed ID: 11792569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
    Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
    J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects.
    Blair HC; Borysenko CW; Villa A; Schlesinger PH; Kalla SE; Yaroslavskiy BB; Garćia-Palacios V; Oakley JI; Orchard PJ
    J Bone Miner Res; 2004 Aug; 19(8):1329-38. PubMed ID: 15231021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.
    Neale SD; Smith R; Wass JA; Athanasou NA
    Bone; 2000 Sep; 27(3):409-16. PubMed ID: 10962353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
    Sankar U; Patel K; Rosol TJ; Ostrowski MC
    J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
    Chu K; Snyder R; Econs MJ
    J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha.
    Hayashi S; Yamada T; Tsuneto M; Yamane T; Takahashi M; Shultz LD; Yamazaki H
    J Immunol; 2003 Nov; 171(10):5130-9. PubMed ID: 14607912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of human osteoclasts in stromal cell-free and stromal cell-rich cultures: differences in osteoclast CD11c/CD18 integrin expression.
    Lader CS; Scopes J; Horton MA; Flanagan AM
    Br J Haematol; 2001 Feb; 112(2):430-7. PubMed ID: 11167844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
    Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
    J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
    Michael H; Härkönen PL; Väänänen HK; Hentunen TA
    J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
    Kudo O; Sabokbar A; Pocock A; Itonaga I; Athanasou NA
    Calcif Tissue Int; 2002 Dec; 71(6):539-46. PubMed ID: 12232680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand.
    Miyamoto T; Arai F; Ohneda O; Takagi K; Anderson DM; Suda T
    Blood; 2000 Dec; 96(13):4335-43. PubMed ID: 11110710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
    Guerrini MM; Sobacchi C; Cassani B; Abinun M; Kilic SS; Pangrazio A; Moratto D; Mazzolari E; Clayton-Smith J; Orchard P; Coxon FP; Helfrich MH; Crockett JC; Mellis D; Vellodi A; Tezcan I; Notarangelo LD; Rogers MJ; Vezzoni P; Villa A; Frattini A
    Am J Hum Genet; 2008 Jul; 83(1):64-76. PubMed ID: 18606301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
    Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
    J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender- and age-related differences in osteoclast formation from circulating precursors.
    Jevon M; Sabokbar A; Fujikawa Y; Hirayama T; Neale SD; Wass J; Athanasou NA
    J Endocrinol; 2002 Mar; 172(3):673-81. PubMed ID: 11874715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis.
    Hirayama T; Danks L; Sabokbar A; Athanasou NA
    Rheumatology (Oxford); 2002 Nov; 41(11):1232-9. PubMed ID: 12421995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The generation of highly enriched osteoclast-lineage cell populations.
    Quinn JM; Whitty GA; Byrne RJ; Gillespie MT; Hamilton JA
    Bone; 2002 Jan; 30(1):164-70. PubMed ID: 11792580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
    Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
    Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.